Skip to content
chrysalis bio logo
Home
About Us
Science & Tech
TP508 Peptide Technology
Radiation Therapy (Brain Cancer)
Respiratory Failure (ARDS)
Nuclear Radiation Exposure
Pipeline
News
Contact
Home
About Us
Science & Tech
TP508 Peptide Technology
Radiation Therapy (Brain Cancer)
Respiratory Failure (ARDS)
Nuclear Radiation Exposure
Pipeline
News
Contact
Read more about the article Novel regenerative peptide TP508 mitigates radiation-induced gastrointestinal damage by activating stem cells and preserving crypt integrity

Novel regenerative peptide TP508 mitigates radiation-induced gastrointestinal damage by activating stem cells and preserving crypt integrity

  • Post author:web-designer
  • Post published:October 23, 2019
  • Post category:Publication

Carla Kantara 1, Stephanie M Moya 1, Courtney W Houchen 2, Shahid Umar 3, Robert L Ullrich 4, Pomila Singh 5, Darrell H Carney 1 6 Affiliations expand PMID: 26280221 PMCID: PMC4626368 DOI: 10.1038/labinvest.2015.103 Abstract In recent years, increasing threats of radiation exposure and nuclear disasters have become…

Continue ReadingNovel regenerative peptide TP508 mitigates radiation-induced gastrointestinal damage by activating stem cells and preserving crypt integrity

Recent Posts

  • Chrysalis BioTherapeutics, Inc. Announces Collaboration with NIAID to Evaluate Chrysalin® for the Treatment of Cutaneous Radiation Injury
  • Chrysalis BioTherapeutics Selected to Present at Respiratory Innovation Summit
  • Chrysalis Receives FDA Approval to Initiate Clinical Trials with Chrysalin™ (TP508)
  • Galveston firm to test potential ‘game-changer’ in lung disease treatment
  • Clinical Trials – Tissue Repair

Recent Comments

    Archives

    • November 2024
    • May 2024
    • September 2023
    • October 2021
    • December 2020
    • August 2020
    • June 2020
    • May 2020
    • October 2019
    • August 2019
    • September 2017
    • October 2016
    • May 2016
    • August 2015

    Categories

    • Press Release
    • Publication

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org
    Let's discuss now
    Get in touch with us
    We respond within 48 hours

    We answer all email and requests as they come in. If you have an urgent matter or would like to place an order please click the link below to give us a call.

    Click here to call us

    About company

    Chrysalis BioTherapeutics, Inc. is committed to helping improve people’s lives through innovation.

    Contact Us
    • 409.497.4083
    • 2200 Market Street, Suite 606 Galveston, Texas 77550
    Menu
    • Home
    • About
    • Pipeline
    • Contact
    Science & Tech
    • Brain
    • Respiratory Failure (ARDS)
    • Nuclear Radiation Exposure
    • TP508 Peptide Technology
    icon of chrysbio

    SEO Agency by Weblify & Webtec

    Facebook-f Twitter
    We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.I agree